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ABSTRACT
A metallic taste is reported by cancer patients as a side effect of systemic therapy. Despite the high
prevalence, this taste alteration has received limited attention. The present study investigated: 1)
the prevalence of metallic taste in cancer patients treated with systemic therapy; 2) possible
predictors of metallic taste; and 3) characteristics of metallic taste. A heterogeneous population of
127 cancer patients, who had received systemic treatment in the past year or were still on
treatment, completed a questionnaire developed for this study. Fifty-eight of 127 (46%) patients
reported taste changes in the preceding week. Of these patients, 20 (34%) reported a metallic taste.
Patients treated with chemotherapy, concomitant radiotherapy, as well as targeted therapy
reported metallic taste. Women experienced metallic taste more often than men. Patients
experiencing a metallic taste also reported more frequently that they were bothered by sour food
and that everything tasted bitter. The experience of metallic taste was highly variable among
patients. In conclusion, metallic taste is a frequently experienced taste alteration by cancer patients.
Patients treated with chemotherapy, concomitant radiotherapy, and targeted therapy are all at risk
for this taste alteration. However, not all patients reported this alteration as bothersome.
Introduction
Taste changes are common in cancer patients as a result of
systemic therapy. Taste changes have been associated with a
decreased appetite, dietary intake, and quality of life (1–7).
The taste perception of cancer patients can be absent (ageu-
sia), decreased (hypogeusia), increased (hypergeusia), dis-
torted (dysgeusia), or taste can be perceived without an
external stimulus (phantogeusia) (8).
Most studies regarding taste changes in cancer patients
have focused on the presence of taste changes in general
(yes/no) or investigated changes in the perception of the pri-
mary tastes sweet, sour, salty, and bitter. A metallic taste is a
typical taste alteration frequently reported by cancer patients
(9). A recent review showed a prevalence of metallic taste
ranging from 10% to 78% in cancer patients treated with
chemotherapy (10). Despite the high prevalence of metallic
taste, this taste alteration has received limited attention. A
cross-sectional study among patients with various cancer
types showed that patients, who reported weight loss since
the start of treatment, were more likely to report an
increased sensitivity to metallic and salty taste, compared to
patients who reported weight gain or no weight change (11).
The consequences of metallic taste regarding food intake,
food preference, and quality of life are unknown. To the best
of our knowledge, no study has focused on metallic taste
speciﬁcally, so far.
The present study aimed to investigate the prevalence
of metallic taste in cancer patients treated with systemic
therapy and to explore possible predictors of metallic
taste regarding age, gender, treatment type, time since
most recent treatment, and factors related to taste
changes. Furthermore, characteristics of metallic taste,
including the perceived intensity, the duration, and con-
sequences regarding food intake were explored.
Methods
Study Population
Cancer patients who had received systemic treatment in
the past year or were still on treatment, with the ability
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to comprehend Dutch (both reading and writing), were
eligible for inclusion. Patients were heterogeneous
regarding cancer type and treatment. During a time
period of 3 wk, all eligible patients were invited to partic-
ipate during their regular follow-up visit at the Medical
Oncology outpatient clinic of the University Medical
Center Groningen. Moreover, eligible hospitalized
patients were asked to participate during a period of
1 wk. During the 3-wk time period that patients visited
the outpatient clinic, all patients were asked to partici-
pate at the discretion of their treating physician. Eligible
patients admitted to the ward were identiﬁed at the dis-
cretion of the attending physician. Patients received the
questionnaire from the treating physician or nurse dur-
ing the outpatient visits or from a researcher during hos-
pitalization. The patients completed the questionnaire
during the visit of the outpatient clinic or during hospi-
talization. The study was conducted in accordance with
the Dutch regulations for research.
Questionnaire
A questionnaire was constructed for the present study,
since no Dutch questionnaire was available that
addressed our speciﬁc research questions. Most ques-
tions were based on the English version of a validated
chemotherapy-induced taste alteration scale (CiTas)
(12). The scale of the Japanese CiTas appeared not to be
appropriate for the Dutch population, since no appropri-
ate translation of the English grading (no, slightly, some-
what, quite, and very) could be established. Therefore,
the scale was altered in a 4-point scale as used in the
questionnaire of the European Organisation for Research
and Treatment of Cancer (EORTC), the EORTC QLQ-
C30 (1 D not at all, 2 D a little, 3 D quite a bit, and 4 D
very much) (13). English questions of the CiTas were
translated into Dutch and back to English by the
researchers and a bilingual physician. Furthermore,
questions concerning the ability to detect taste, food
aversions, factors that might affect taste (e.g., dry
mouth), and metallic taste were added (8,14,15). Adapta-
tions regarding responding scales were made to make
the questionnaire uniform. An initial draft of the ques-
tionnaire was reviewed by an experienced panel consist-
ing of ﬁve researchers in the ﬁeld of tasting, a medical
oncologist, and a data analyst. Next, the draft of the
questionnaire was pilot-tested among 30 cancer patients,
heterogeneous in age, cancer type, and treatment, to
ensure all questions were clear and were interpreted as
intended. Based on this pilot, several questions were
added or adapted. For example, the questions regarding
trouble keeping food down and dry mouth were added,
since several patients came up with these symptoms
related to their taste changes. Moreover, examples of cer-
tain foods that raise an aversion (such as the question
“Sweet food bothers me”) were removed from the ques-
tionnaire, as several patients based their answers on the
examples of foods instead of the taste.
The ﬁnalized 47-item questionnaire consisted of three
parts (see Supplementary Material). The ﬁrst part con-
tained eight questions regarding disease and treatment.
The last question of the ﬁrst part was: “Have you experi-
enced a change in taste since your diagnosis?” When
patients ticked the box “yes,” they experienced a change
in taste somewhere during their course of the disease. All
patients ﬁlled out this part. The second part consisted of
30 closed questions regarding taste, smell, appetite, food
aversions, and factors associated with taste. This part
was only ﬁlled out by patients who reported to have taste
changes in the preceding week. This time window was
used to minimize the relay on memory to assess a recent
and precise experienced taste sensation. The last two
questions of the second part were: “Have you experi-
enced certain foods to taste differently than before your
diagnosis?” and “Have you experienced a continuous
taste in your mouth that you did not experience before
your diagnosis?” The response options included: blood,
bitter, something chemical, something musty, drugs,
metallic, sweet, salty, sour, and “other, namely.” Multiple
answers were possible. Patients who ticked the box
“metallic” for one of these questions or for both ques-
tions were deﬁned as experiencing a metallic taste. Only
this last category of patients ﬁlled out the last part of the
questionnaire. This third part contained ﬁve statements
regarding the intensity, the consequences regarding the
ability to eat in general and certain foods, and the evoked
sensation (by food products or a continuous sensation)
of metallic taste using the same 4-point scale as previ-
ously mentioned.
Statistical Analysis
Descriptive statistics are presented as mean § stan-
dard deviation or percentages. Multiple logistic
regression (forward stepwise likelihood ratio method)
was used to investigate the relation between metallic
taste and several parameters listed in the following
sections. Two models were used. The ﬁrst model
explored the relation between metallic taste and char-
acteristics of patients and treatment. The model
included the following parameters: age, gender, treat-
ment type, and time since most recent treatment (N
D 58). The second model additionally included the
responses regarding taste changes and factors associ-
ated with taste changes. Patients who ﬁlled out “I do
not know” at one or more questions were excluded
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from analysis, resulting in 38 patients included in
model 2. As this number of patients is low compared
to the number of tested parameters, overﬁtting may
occur. Therefore, a third analysis was used with only
signiﬁcant parameters from model 2 to maximize the
sample size. The model included only age, gender,
treatment type, time since most recent treatment, and
the response on “sour food bothers me,” “fatty food
bothers me,” and “everything tastes bitter” (N D 54).
To explore the relation between metallic taste and
treatment type, treatments were divided into the fol-
lowing treatment groups: platinum-based chemother-
apy, taxane-based chemotherapy, other
chemotherapy, hormonal therapy, tyrosine kinase
inhibitor therapy, other targeted therapy, and con-
comitant systemic treatment with radiotherapy. The
time since most recent treatment was divided into
less than 1 mo ago, between 1 and 3 mo ago, and
more than 3 mo ago. Patients who received daily
treatment were grouped into the category of most
recent treatment less than 1 mo ago. Statistical anal-
yses were performed using SPSS, version 22 (SPSS
Inc. Chicago, IL). A two-tailed P-value <0.05 was
considered statistically signiﬁcant.
Results
Characteristics of Study Population
A total of 255 patients were asked to participate in the
study. Of these patients, 127 (50%) ﬁlled out the ques-
tionnaire. The characteristics of the patients are shown
in Table 1.
Prevalence of Taste Changes
Of the 127 cancer patients, 79 (62%) reported taste
changes since diagnosis. Of these 79 patients, 58 (46% of
total) had taste changes in the preceding week.
Of the 127 patients, 20 (16%) patients (5 male, 15
female) reported a metallic taste in their mouth and/or
that food had a metallic taste. Thus, 34% of the 58
patients who had taste changes in the preceding week
experienced a metallic taste (since only patients who
reported to have taste changes in the preceding week
ﬁlled out the questions regarding metallic taste).
Patients treated with chemotherapy, concomitant
radiotherapy, as well as targeted therapy reported
metallic taste with a prevalence of at least 10%
(Table 2). Of all treatments, taxane-based chemother-
apy had the highest prevalence of metallic taste (4 out
of 9; 44%).
Characteristics of Metallic Taste
Table 3 displays the responses of 19 patients (one patient
reporting metallic taste did not ﬁll out the last part of the
questionnaire) to the statements concerning the charac-
teristics of metallic taste. A high diversity was found
across patients regarding the perceived intensity, the
consequences regarding the ability to eat in general or
certain foods, the evoked sensation, and the duration.
Eight of 19 patients reported that metallic taste was one
of the most negative aspects of their taste changes.
Table 1. Characteristics of the patients.
Cancer patients (N D 127)
Age (years), mean § SD 56.8§ 13.7
Gender, male N (%) 54 (43)
Treatment group, N (%)
Platinum-based CT 27 (21)
Taxane-based CT 9 (7)
Other CT 33 (26)
Hormonal therapy 13 (10)
TKI treatment 13 (10)
Other targeted treatment 23 (18)
Concomitant radiotherapy 9 (7)
Most recent treatment, N (%)
<1 mo ago 109 (86)
Between 1 and 3 mo ago 8 (6)
>3 mo ago 10 (8)








Duration of treatment (HT and TT), N (%)
<1 mo 4 (8)
Between 1 and 3 mo 17 (35)
>3 mo 28 (57)
CT, chemotherapy; TKI, tyrosine kinase inhibitors; HT, hormonal therapy; TT,
targeted therapy.






N (% of TG)
Taste changes
preceding week






27 20 (74) 12 (44) 4 (15)
Taxane-based
CT
9 7 (78) 6 (67) 4 (44)
Other CT 33 21 (64) 17 (52) 6 (18)
Hormonal
therapy
13 9 (69) 5 (39) 2 (15)
TKI treatment 13 7 (54) 7 (54) 1 (8)
Other targeted
treatment
23 11 (48) 8 (35) 2 (9)
Concomitant
radiotherapy
9 4 (44) 3 (33) 1 (11)
CT, chemotherapy; TKI, tyrosine kinase inhibitors.
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Predictors of Metallic Taste
Logistic regression with age, gender, treatment group,
and time since most recent treatment as independent
variables (N D 58) showed that gender was signiﬁcantly
associated with metallic taste (Table 4). Women reported
metallic taste more often than men. The second model
(N D 37) showed that patients experiencing a metallic
taste reported that they were bothered by sour and fatty
foods and that everything tasted bitter, more often
(Table 5). In the third model (N D 54), only the aversion
to sour foods and the bitter taste remained signiﬁcant
related to metallic taste (Table 6).
Discussion
One-third of all patients with taste changes and 16% of
all patients reported metallic taste in this heterogeneous
group of cancer patients. Previous studies have shown a
prevalence of metallic taste in cancer patients treated
with chemotherapy ranging from 10% to 78% (16–22).
Also, metallic taste in patients treated with radiotherapy
has been reported previously (23). To our knowledge,
this is the ﬁrst study that reports metallic taste in patients
receiving targeted therapy.
Metallic taste is a much-discussed topic on cancer
patient forums. Some patients who experience metallic
taste ask desperately for help on these forums to obtain
information regarding suitable management strategies.
In the present study, the experience of metallic taste was
highly variable across the patients. Metallic taste seems
not to be bothersome for all patients.
Cancer patients who experienced metallic taste reported
more often that everything tasted bitter. In other studies,
“metallic or bitter taste” has been reported as a taste alter-
ation instead of “metallic taste” only. Our data conﬁrm that
metallic taste and bitter taste are closely related.
Women reported metallic taste more often than men.
Also, previous studies performed in cancer patients
found that taste changes were more prevalent in women
compared to men (7,11,16), whereas other studies found
no gender differences (3,22). A study in 89 lung cancer
patients showed that women reported more often stron-
ger sensations, while men reported weaker sensations
more frequently (24). Reasons for gender differences
regarding taste changes are currently unknown. In gen-
eral, there is evidence that women have a greater taste
and smell sensitivity than men (25,26). Therefore, female
cancer patients may be more prone to changes in taste
function than men.
The participation rate of ﬁfty percent was quite low in
the present study. Patients were asked to participate dur-
ing regular outpatient visits or hospitalization. Since no
Table 3. Responses to the statements (frequency, N) concerning
the characteristics of metallic taste: perceived intensity, sensation
evoked by food products, continuous sensation, consequences
regarding the ability to eat in general, consequences regarding











Is intense 1 13 5 — —
Becomes stronger
when I eata




4 14 1 — —
Bothers me with
food in general
7 5 5 1 1
Bothers me only
with certain foods
6 6 4 1 2
Duration metallic
taste
<1 wk 1 wk to 1
mo
1–3 mo >3 mo I do not
know
1 7 4 4 3
aN D 18.
Table 4. Predictors of metallic taste including age, gender, treat-
ment group, and time since most recent treatment in the logistic
model (N D 58).
95% CI for odds ratio
Included B (SE) Lower Odds ratio Upper
Constant ¡1.53 (0.49)
Gender 1.53 (0.61) 1.38 4.60 15.32
Table 5. Predictors of metallic taste including age, gender, treat-
ment group, time since most recent treatment, and factors asso-
ciated with taste changes in the logistic model (N D 38).
95% CI for odds ratio
Included B (SE) Lower Odds ratio Upper
Constant ¡19.89 (8.43)
Gender 4.88 (2.43) 1.13 130.95 15235.98
Sour food bothers me 2.78 (1.37) 1.11 16.17 234.70
Fatty food bothers me 1.99 (1.09) 0.86 7.32 62.30
Everything tastes bitter 5.28 (2.39) 1.81 195.80 21141.98
Table 6. Predictors of metallic taste including age, gender, treat-
ment group, time since most recent treatment, and the three
questions related to metallic taste derived from the second
model in the logistic model (N D 54).
95% CI for odds ratio
Included B (SE) Lower Odds ratio Upper
Constant ¡5.49 (1.59)
Gender 2.03 (0.80) 1.59 7.59 36.36
Sour food bothers me 0.88 (0.41) 1.07 2.41 5.42
Everything tastes bitter 1.81 (0.87) 1.13 6.14 33.44
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extra time was scheduled for the present study, the
recruitment of patients was added to the regular work of
the treating physicians and nurses. Moreover, not all out-
patient visits were suitable to recruit patients (e.g., after
discussing progressive disease).
Patients reporting metallic taste reported that they
were bothered by sour and fatty foods, more frequently.
However, the association between metallic taste and the
aversion to fatty foods needs to be interpreted carefully,
since the sample size was small in the logistic model
including factors associated with taste changes. Health
care professionals can draw attention to the risk of an
aversion to these foods to support patients experiencing
a metallic taste. The following management strategies
can be advised when patients suffer from a metallic taste:
the use of plastic utensils; to eat cold or frozen foods;
adding strong herbs, spices, sweetener, or acid to foods;
eating sweet and sour foods; to use “miracle fruit” sup-
plements; and to rinse with chelating agents (10). The
use of sour foods and adding sour taste to foods is in
contradiction to the present ﬁnding that patients who
experienced metallic taste more often reported that they
were bothered by sour foods. Future studies are needed
to clarify this possible relationship.
Metallic sensations have also been reported as a side
effect of drugs (27) and throughout pregnancy (28).
Moreover, metallic taste might be elicited by oral yeast
infections (29), burning mouth syndrome (30), damage
by stapedectomy or anesthesia of the chorda tympani
(31,32), artiﬁcial sweeteners (33), and dental amalgam
ﬁllings (34). These factors may have inﬂuenced the prev-
alence of metallic taste in the current study. However,
only patients who experienced taste changes in the pre-
ceding week completed the questionnaire with regard to
metallic taste and were asked to reﬂect on new symptoms
previously unknown to them. Therefore, the reported
metallic taste may be due to drug effects or infection, but
not due to the other above-mentioned causes.
In conclusion, metallic taste is a side effect of systemic
therapy that is not commonly addressed by health care
professionals. However, one-third of all patients with
taste changes and 16% of all patients reported metallic
taste during their treatment. Patients treated with che-
motherapy, concomitant radiotherapy, hormonal ther-
apy, and other targeted therapy are all at risk of
experiencing a metallic taste. However, not all patients
ﬁnd this type of taste alteration bothersome.
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